Journal of Clinical Pharmacy and Therapeutics

Research Article

A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease

Table 1

The basic characteristics of inclusion in the literature.
NoStudyYearNationDurationPatientsInterventionNumber (F/M)AgeCourse of treatmentRandomOutcomes
Experimental groupControl groupExperimental groupControl groupExperimental groupControl group
1Akira Sezai2013Japan—CKD4 complicated with HUAFebuxostatAllopurinol13/5812/5767.4 ± 9.766.4 ± 10.86 monRCT①②
2Akira Sezai2015Japan—CKD3 complicated with HUAFebuxostatAllopurinol13/4311/4269.4 ± 10.069.1 ± 9.26 monRCT①②
3Kenichi Tanaka2015Japan2012.04–2013.03CKD3 complicated with HUAFebuxostatAllopurinol2/193/1670.1 ± 9.566.1 ± 7.03 monRCT②
4Yang Jie2017China2015.11–2016.05CKD3-4 complicated with HUAFebuxostatAllopurinol10/2012/1842.5 ± 12.144.1 ± 11.52 monRCT②④
5Zhang XuHong2018China2014.08–2016.02CKD1-3 complicated with HUAFebuxostatAllopurinol11/237/2776.5 ± 7.974.8 ± 8.96 monRCT④
6Liu Min2019China2016.12–2017.08CKD1-3 complicated with HUAFebuxostatAllopurinol13/3312/3466.2 ± 5.367.5 ± 4.96 monRCT④
7Tan Zhao2019China2015.02–2016.12CKD3 complicated with HUAFebuxostatAllopurinol7/329/3054.2 ± 9.755.8 ± 10.16 monRCT①③④
8Wang HuiFang2019China2015.06–2016.06CKD3-5 complicated with HUAFebuxostatAllopurinol14/3717/3051.39 ± 15.0452.72 ± 15.126 monRCT②③④
9Xian Wei2019China2015.10–2017.10CKD1-3 complicated with HUAFebuxostatAllopurinol23/3125/2966.4 ± 7.367.2 ± 7.56 monRCT①②④⑤
10Yin Yong2019China2016.01–2017.09CKD4-5 complicated with HUAFebuxostatAllopurinol14/2913/3047.38 ± 6.5047.58 ± 6.602 monRCT①④⑤
11Ni Man2020China2018.08–2019.08CKD complicated with HUAFebuxostatAllopurinol22/3120/3361.09 ± 4.8761.32 ± 5.196 monRCT①④
12Wang Fan2020China2016.08–2019.08CKD1-3 complicated with HUAFebuxostatAllopurinol10/4011/3970.7 ± 6.270.4 ± 6.16 monRCT①②④⑤
13Zhang Qing2020China2017.01–2019.05CKD2-4 complicated with HUAFebuxostatAllopurinol12/1814/1656.00 ± 12.0051.00 ± 15.006 monRCT①②④⑤
14Bao Qun2021China2019.01–2019.12CKD3-5 complicated with HUAFebuxostatAllopurinol20/3217/3358.65 ± 0.4758.86 ± 0.516 monRCT①②③④
15Zhang YiWen2021China2016.08–2019.01CKD4-5 complicated with HUAFebuxostatAllopurinol35/3233/3455.1 ± 9.454.2 ± 8.46 monRCT①②③④⑤
16Zeng JiRen2021China2020.06–2020.12CKD complicated with HUAFebuxostatAllopurinol19/2118/22——6 monRCT⑤
17Kang JingJing2021China2018.02–2020.06CKD2-4 complicated with HUAFebuxostatAllopurinol20/2518/2764.21 ± 2.1464.16 ± 2.126 monRCT④
18Wang Nan2022China2020.03–2021.01CKD4-5 complicated with HUAFebuxostatAllopurinol208/4922/4781.35 ± 2.5281.40 ± 2.491 monRCT②④⑤
RCT: randomized controlled trial; F/M: female/male; CKD: chronic kidney disease; HUA: hyperuricemia; ① SCr, serum creatinine; ② eGFR, estimated glomerular filtration rate; ③ 24-h UPQ, 24-hour urinary protein quantity; ④ SUA, serum uric acid; ⑤ BUN, blood urea nitrogen.